EASIX-1year and late mortality after allogeneic stem cell transplantation

•EASIX assessed at 1 year after allo-SCT identifies patients at high risk for late NRM.•These findings suggest an important role of the endothelium for late NRM in long-term survivors after allo-SCT. [Display omitted] Patients with hematological malignancies who survive the first year after allogene...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood advances 2023-09, Vol.7 (18), p.5374-5381
Hauptverfasser: Kordelas, Lambros, Terzer, Tobias, Gooley, Ted, Davis, Chris, Sandmaier, Brenda M., Sorror, Mohamed, Penack, Olaf, Schaeper, Nigel D. E., Blau, Igor W., Beelen, Dietrich, Radujkovic, Aleksandar, Dreger, Peter, Luft, Thomas
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•EASIX assessed at 1 year after allo-SCT identifies patients at high risk for late NRM.•These findings suggest an important role of the endothelium for late NRM in long-term survivors after allo-SCT. [Display omitted] Patients with hematological malignancies who survive the first year after allogeneic stem cell transplantation (allo-SCT) without relapse have a substantial risk of nonrelapse mortality (NRM) and missing predictive markers. The Endothelial Activation and Stress Index (EASIX) predicts endothelial complications and NRM early after allo-SCT. We hypothesized that EASIX assessed 1 year after allo-SCT in survivors who were disease free may predict late NRM. Survivors who were relapse-free at 1 year after allo-SCT were retrospectively studied in 2 independent cohorts (training cohort, n = 610; merged validation cohort, n = 852). EASIX determined 1 year after allo-SCT correlated with the overall survival (OS), NRM, and relapse. Serum endothelial and inflammatory markers were measured in the training cohort and correlated with EASIX-1year, which predicted OS and NRM but not relapse risk in both the training and validation cohorts in univariable and multivariable Cox regression analyses. Brier score and c-index analyses validated the univariable EASIX effects. There was no significant interaction between EASIX-1year and incidence of chronic graft-versus-host disease (GVHD) on OS. EASIX-1year predicted the outcome irrespective of preexisting comorbidities. Principal causes of NRM in both training and validation cohorts were infections with and without GVHD as well as cardiovascular complications. EASIX-1year correlated with sCD141 and interleukin-18 but not with C-reactive protein, suppressor of tumorigenicity-2, angiopoietin-2, CXCL9, or CXCL8. To our knowledge, EASIX-1year is the first validated predictor of late overall and NRM. Patients who are high risk as defined by EASIX-1year might be considered for intensified surveillance and prophylactic measures.
ISSN:2473-9529
2473-9537
2473-9537
DOI:10.1182/bloodadvances.2022008617